WLC

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Retrieved on: 
火曜日, 5月 7, 2024
Congress, Patient, Cystoscopy, HAL, University Challenge 2013–14, Meta-analysis, Risk, Urinary bladder, WLC, Survival, Health care, Recurrence, Pivotal trial, BLC, BCG, CIS, Bladder cancer, Detection, Principal, Access, AUA, BRAVO, RCT, Clinical trial, Overalls, Medical imaging

On Sunday, May 5th, Dr. Sanjay Das presented the study, "Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis."

Key Points: 
  • On Sunday, May 5th, Dr. Sanjay Das presented the study, "Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis."
  • The study addresses a lack of practical real-world data comparing the impact of BLC versus WLC, specifically for recurrence, progression, and survival.
  • The results of this study confirm that BLC use is associated with positive and statistically significant impacts on these outcomes.
  • A total of 177 patients were enrolled, 128 patients underwent blue light cystoscopy (BLC) with Cysview (HAL) and were included in the full analysis set.

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Retrieved on: 
火曜日, 5月 7, 2024
Congress, Patient, Cystoscopy, HAL, University Challenge 2013–14, Meta-analysis, Risk, Urinary bladder, WLC, Survival, Health care, Recurrence, Pivotal trial, BLC, BCG, CIS, Bladder cancer, Detection, Principal, Access, AUA, BRAVO, RCT, Clinical trial, Overalls, Medical imaging

On Sunday, May 5th, Dr. Sanjay Das presented the study, "Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis."

Key Points: 
  • On Sunday, May 5th, Dr. Sanjay Das presented the study, "Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis."
  • The study addresses a lack of practical real-world data comparing the impact of BLC versus WLC, specifically for recurrence, progression, and survival.
  • The results of this study confirm that BLC use is associated with positive and statistically significant impacts on these outcomes.
  • A total of 177 patients were enrolled, 128 patients underwent blue light cystoscopy (BLC) with Cysview (HAL) and were included in the full analysis set.

Whistleblower Law Collaborative Spring Update

Retrieved on: 
水曜日, 5月 1, 2024
AmerisourceBergen, CFTC, Boston Bar Association, WLC, Conference, FCA, McKesson Corporation, White collar, American Bar Association, DOJ, Multimedia, False Claims Act, Fraud, Pharmaceutical industry

BOSTON, May 1, 2024 /PRNewswire/ -- Whistleblower Law Collaborative LLC is now representing whistleblowers in emerging new practice areas including cryptocurrency fraud, anti-money laundering and sanctions evasion, and cybersecurity fraud .

Key Points: 
  • BOSTON, May 1, 2024 /PRNewswire/ -- Whistleblower Law Collaborative LLC is now representing whistleblowers in emerging new practice areas including cryptocurrency fraud, anti-money laundering and sanctions evasion, and cybersecurity fraud .
  • This spring marked Erica's fifth year teaching the popular Health Care Fraud & Abuse seminar at Boston University School of Law.
  • WLC has become one of the most recognized and successful whistleblower firms in the country.
  • Whistleblower Law Collaborative LLC , based in Boston, devotes its practice entirely to representing clients nationwide in bringing actions under the federal and state whistleblower laws and programs, False Claims Acts , and other whistleblower programs including those addressing financial fraud.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
木曜日, 3月 28, 2024
NMIBC, Biopsy, BLC, TURBT, Patient, Skin, WLC, MD, Cancer, Bladder cancer, Pathology

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
木曜日, 3月 28, 2024
NMIBC, Biopsy, BLC, TURBT, Patient, Skin, WLC, MD, Cancer, Bladder cancer, Pathology

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

Retrieved on: 
月曜日, 1月 29, 2024
WLC, BLC, ASCO, RCT, CIS, Patient, Randomized controlled trial, Diagnosis, Society, Bladder cancer, RWS

The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.

Key Points: 
  • The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.
  • A total of 114 patients were in the full analysis set.
  • Nineteen patients were included in the real-world study (RWS).
  • The new drug application (NDA) for APL-1706 was accepted by the National Medical Products Administration (NMPA) in November 2023.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
水曜日, 11月 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
水曜日, 11月 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

T1 E1 Network Test Solution Capabilities

Retrieved on: 
木曜日, 11月 2, 2023
CAS, DCE, Linux, PC, WCS, DTE, GSM, Analyser, Command-line interface, SSH, FXS, GL, Telephone, Python, Unix, WLC, PPP, Maintenance, USB, Frame Relay, SS7, Microsoft Windows, Telecom, PowerShell, ISDN, SS1, FXO, Probe, Collection, HDLC, Automation, Data analysis, Communication, Console, Emulation, Mobile phone, Video game, Internet service provider, Computer data storage, Computer network

“GL's tProbe™ is a test and measurement device for T1 E1 networks.

Key Points: 
  • “GL's tProbe™ is a test and measurement device for T1 E1 networks.
  • GL's Windows Client/Server (WCS) software allows T1 E1 analysis and emulation cards with remote operation, automation, and multi-site connectivity capabilities.
  • It sends commands to T1 E1 WCS servers and shows the responses in Console, PowerShell, or Terminal Windows.
  • Available with Dual T1 or E1, FXO, FXS, DTE and DCE interfaces
    Bit Error Rate Testing over all timeslots.

Incline Partners with White Label Communications

Retrieved on: 
火曜日, 10月 24, 2023
Member of the Scottish Parliament, Incline, MSP, SMS, Managed services, Partnership, WLC, Atlas, The Company, Voice over IP

PITTSBURGH, Oct. 24, 2023 /PRNewswire/ -- Incline Equity Partners ("Incline"), a leading private equity firm dedicated to investing across the middle market, is pleased to announce its partnership with White Label Communications ("WLC" or the "Company"), a provider of private label communication solutions to Managed Service Providers ("MSPs").

Key Points: 
  • PITTSBURGH, Oct. 24, 2023 /PRNewswire/ -- Incline Equity Partners ("Incline"), a leading private equity firm dedicated to investing across the middle market, is pleased to announce its partnership with White Label Communications ("WLC" or the "Company"), a provider of private label communication solutions to Managed Service Providers ("MSPs").
  • Our partnership with Incline will provide continued investment and expertise to advance our technology platform.
  • "White Label Communications was founded in 2011 to create a simple solution for private label unified communications," said Tom Joseph, Founder and CEO of WLC.
  • "Our partnership with Incline will provide continued investment and expertise to advance our technology platform, further enabling our MSP partners to grow their businesses."